Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Melanoma treatment details. Chemotherapy. Mary Crowley Cancer Research Center, Dallas, TX, United States

Survival: 7.6 months
Toxicity Grade: 5
Treatments: Chemotherapy
Country: United States
City/State/Province: Dallas, TX
Hospital: Mary Crowley Cancer Research Center
Journal: Link
Date: 7/2009

There were 74 patients with metastatic melanoma involved in this Phase II trial. Of these, 50 (67.6%) were male. The median patient age was 58 years old, with a range of 27-79.

Patients were given a combination of two chemotherapeutic drugs, cisplatin and talabostat. Talabostat is an agent that stimulates the immune system to kill cancer cells.

During this study, 39 (52.7%) patients died, the majority of these deaths (36 of 39) resulting from progressive disease. In addition, adverse events of Grade 3 or higher were experienced by 56.8% of patients. These effects included anemia, thrombocytopenia, neutropenia, and tinnitus (ringing in the ears).

The median overall survival in this study was 7.6 months.

Two of the authors are employed by Point Therapeutics, Inc., makers of talabostat.

Correspondence: Dr. John Nemunaitis

E-mail to a Friend Email Physician More Information